Stock CYTK CYTOKINETICS, INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Real-time Estimate Cboe BZX
Other stock markets
 11:23:00 2024-06-04 am EDT 		5-day change 1st Jan Change
48.08 USD -3.58% Intraday chart for Cytokinetics, Incorporated +0.18% -42.15%
01:42pm B. Riley Cuts Price Target on Cytokinetics to $92 From $122, Maintains Buy Rating MT
Jun. 03 Cytokinetics Insider Sold Shares Worth $635,978, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Cytokinetics Insider Sold Shares Worth $635,978, According to a Recent SEC Filing
Cytokinetics Closes $500 Million Stock Offering
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Tech Stocks Rally on NVIDIA Earnings
Top Premarket Decliners
Cytokinetics Prices $500 Million Common Stock Offering
Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline
Cytokinetics Plans $500 Million Common Stock Offering -- Shares Drop After Hours
Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors
Cytokinetics Q1 Net Loss Narrows, Revenue Declines
Cytokinetics, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024
Cytokinetics, Incorporated Announces Topline Data from Phase 1 Clinical Study of Ck-4021586
Cytokinetics, Incorporated Announces CEDAR-HCM Is Open to Enrollment
Cytokinetics Insider Sold Shares Worth $1,012,265, According to a Recent SEC Filing
Cytokinetics Appoints Sung Lee as CFO
Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024
Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing
Sector Update: Health Care Stocks Rise Friday Afternoon
Cytokinetics Reports Positive Follow-On Data for Prospective Heart Medication; Shares Rise
Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYTK Stock
  4. News Cytokinetics, Incorporated
  5. Other languages